Healthcare Industry News:  MicroThermX 

Devices Oncology

 News Release - January 18, 2011

BSD Medical Reports First European Sale of MicroThermX Microwave Ablation System to Med-Italia Biomedica

SALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) (, a leading provider of medical systems that utilize heat therapy to treat cancer, today announced the sale and shipment of the MicroThermX Microwave System to Med-Italia Biomedica (Med-Italia), one of the largest interventional radiology/oncology distributors in Italy. This is the first European sale of BSD's MicroThermX Microwave System. BSD personnel will be attending the premiere European clinical use of the system, which will involve the treatment of a patient with a large hepatic tumor. The treatment will be carried out by a key physician in Torino, Italy. Med-Italia ( is a major distributor and manufacturer of products designed for the interventional radiology and oncology market in Italy. They are an exclusive distributor in Italy for a number of large medical companies, selling strategically adjacent products to the same clinicians and market that will be targeted for the MicroThermX System.

BSD is in the final process of establishing both domestic and international distribution networks dedicated to selling its new microwave ablation product line. BSD has elected to pursue the strategy of utilizing a network of leading specialty distribution firms who are focused on selling products in the field of interventional radiology, the target market for the Company’s ablation product line. To support the global distribution network for the MicroThermX product line, the Company is increasing its marketing and sales staff. Additional marketing and sales resources will provide effective hands-on field training and management of the distribution network and the large number of sales personnel that this new distribution network will bring to BSD Medical.

About the MicroThermX Microwave Ablation System

The MicroThermX Microwave Ablation System (MTX-180) is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MTX-180 is the first of its kind that allows delivery of higher power levels using a single generator. The MTX-180 utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MTX-180 introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MTX-180 for ablation of soft tissue. BSD has also received CE Marking for the MTX-180 System. CE marking approval allows BSD to market the MTX system in the 30 countries that comprise the European Union (EU) and the European Free Trade Association (EFTA). CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MTX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Source: BSD Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.